Key result
The triglyceride-glucose index serves as a valuable non-invasive biomarker strongly associated with the incidence, prognosis, and mortality of heart failure and other cardiovascular diseases.
Why the study?
The value of the TyG index in heart failure patients treated with SGLT2 inhibitors has not been systematically evaluated.
Answers are grounded in this paper and cite their sources.
This review highlights the potential of the TyG index as a prognostic biomarker in heart failure and discusses its relevance in the context of modern therapies like SGLT2 inhibitors.
The triglyceride-glucose (TyG) index, proven to be a crucial insulin resistance biomarker (better than the Homeostasis Model Assessment for Insulin Resistance), is simple and non-invasive. Recently, indisputable evidence has shown that the TyG index is strongly associated with cardiovascular disease [CVD, including atherosclerosis, heart failure (HF), and hypertension] prognosis and mortality. Nevertheless, the value of the TyG index in HF patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) has not been systematically evaluated. Therefore, in this review, we summarized the value of the TyG index and its related parameters as markers of CVD, especially HF. Furthermore, we addressed the use of SGLT2is and GLP-1 receptor antagonists in HF patients. Finally, we summarized the mechanism of the "obesity paradox."
No takes yet. Share an insight, caveat, or question.
Fang et al. (2024) conducted a review in Heart failure. Triglyceride-glucose (TyG) index was evaluated. The triglyceride-glucose index serves as a valuable non-invasive biomarker strongly associated with the incidence, prognosis, and mortality of heart failure and other cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: